Asieris Pharmaceuticals

Approved

Shanghai, United StatesFounded 2010asieris.com

Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.

Founded

2010

Focus

Small Molecules

AI Company Overview

Technology Platform

Asieris employs multiple proprietary platforms: TIMN for immunomodulator discovery in cancer/autoimmunity, TAIDD for AI-driven small-molecule drug discovery, PADD for prodrug delivery, and DDC for fragment-based drug discovery and chimeras.

Funding History

Total raised: $220M

Series C$120MLilly Asia VenturesSep 15, 2021

Series B$70MOrbiMedDec 15, 2020

Series A$30MQiming Venture PartnersJun 15, 2019

Opportunities

Significant opportunities exist in expanding Cevira® globally (EMA MAA is a key step) and advancing its deep pipeline, particularly the 'best-in-class' candidate APL-2401 in the high-value FGFR-altered tumor space.

The company's technology platforms also offer opportunities for out-licensing and strategic partnerships.

Risk Factors

Key risks include clinical trial failures across the pipeline, regulatory setbacks for Cevira® in international markets, commercialization challenges in a competitive landscape, and the inherent uncertainties of drug development and global market access.

Competitive Landscape

Asieris faces competition from standard surgical care in cervical precancer, other intravesical therapies in bladder cancer, and approved FGFR inhibitors. Its differentiation lies in its specialized focus, first-in-class non-invasive product (Cevira®), and platform-derived candidates designed for superior selectivity and safety (e.g., APL-2401).